feedback
facebook page
Follow Me on Pinterest
twitter page
google plus page
rss feed

Recalled Product

Item detail and remedy information

Search Recalls or Browse by Category
Consumer Products (?)
Food & Health (?)
Vehicles (?)
Home > Recalled Products > Drugs > Elevated Impurity > Macleods Losartan Potassium USP Tablets And Losartan Potassium/Hydrochlorothiazide Combination Tablets

Recall: Macleods Losartan Potassium USP Tablets And Losartan Potassium/Hydrochlorothiazide Combination Tablets

email
email

On 2019-06-26, the FDA announced that Macleods Pharmaceutical Limited is conducting a recall on Losartan Potassium USP Tablets And Losartan Potassium/Hydrochlorothiazide Combination Tablets due to a possible . The recalled products were sold under the brand name(s) Macleods during an unspecified time period throughout the regions shown in the map below.

In recent months, there have been 4 drugs recalls due to potential elevated impurity, including losartan potassium tablets, losartan potassium 25 mg and 100 mg tablets usp and more. Additionally, there have been 18 drug and medical device recalls due to other health hazards as well as 66 food recalls.

Email Me About Recalls On:
Food  |  Drugs  |  Medical Devices  |  Pet Care Products  |  All of These


Macleods Pharmaceuticals Limited Losartan Potassium and Hydrochlorothiazide Tablets, Label
Note: Images may not be available for every version. Please review the detailed description below.

Company Contact Information:

Name: Macleods Pharmaceutical Limited
Phone: 855-926-3384

Do you work for a company involved with this recall? Contact us to learn how you can control data, information and ads shown on this page.

Detailed Recall Information



Regions Where Sold: Nationwide

Product Description: Losartan Potassium USP tablets and Losartan Potassium/Hydrochlorothiazide combination tablets

Brand Name(s): Macleods

Reason for Recall: NMBA impurity

Official Recall Date: 2019-06-26


Advertisement

Additional information provided by the FDA.gov:

Macleods Pharmaceuticals Limited has initiated a voluntary recall in the United States, to the patient level, of 32 lots of Losartan Potassium USP Tablets (2 lots of 50mg strength) and Losartan Potassium/Hydrochlorothiazide combination Tablets (12 lots of 50mg/12.5mg strength, 3 lots of 100mg/12.5mg strength and 15 100mg/25mg strength) to the patient level due to the detection of trace amounts of an unexpected impurity, N-Nitroso-N-methyl-4-aminobutyric acid (NMBA). The impurity was found in 32 lots of active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited that is above the US Food & Drug Administration's interim acceptable exposure limit of 9.82 ppm. Based on the available information, the risk of developing cancer in a few patients following long-term use of the product cannot be ruled out. Read More.


More information may be available at FDA.gov
Advertisement


Latest Safety Recalls

Select image for details, including additional styles.

 

Advertisement

Comments

Do you have comments or questions about this recall? Share them here.
Note: The recalling companies may not be monitoring these comments; they should be directed toward the public. Community Guidelines apply.
comments powered by Disqus
Back to Top



Sources may include Food & Drug Administration (FDA), United States Department of Agriculture (USDA), Health Canada and companies involved with this or a related recall.

Search Recalled Products or Browse by Category
Consumer Products (?)
Food & Health (?)
Vehicles (?)
Latest Product Recalls
Consumers
Register Products
Check for Recalls
Find Resources
Brands & Retailers
Connect to Customers

Consignment Sales
Check Inventory
Install Recall Finder
Take Safety Pledge

Home Inspectors
Check Appliances
Developers
APIs & Feeds
Recall Search for Web
Recall Search for Mobile
Facebook Apps

Researchers
Product Recall Statistics
About
Company
Contact
Press
Blog

Social
Facebook
Twitter